123 related articles for article (PubMed ID: 34412070)
1. Cytoplasmic P120ctn Promotes Gefitinib Resistance in Lung Cancer Cells by Activating PAK1 and ERK Pathway.
Liu WW; Hu J; Wang R; Han Q; Liu Y; Wang S
Appl Immunohistochem Mol Morphol; 2021 Nov-Dec 01; 29(10):750-758. PubMed ID: 34412070
[TBL] [Abstract][Full Text] [Related]
2. PTP-PEST Regulated Membranous/Cytoplasmic Translocation of p120ctn in the Lung Cancer Resistance to Tyrosine Kinase Inhibitor.
Liu WW; Hu J; Zhao Y; Wang R; Han Q; Rong XZ; Wang SY; Wang EH; Wu MX; Wang S; Liu Y
Appl Immunohistochem Mol Morphol; 2022 Mar; 30(3):215-224. PubMed ID: 35030104
[TBL] [Abstract][Full Text] [Related]
3. The Expression Pattern of p120-Catenin is Associated With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Liu Y; Wang S; Dong QZ; Liu N; Han Y; Zhang XP; Fan CF; Wang EH
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):64-70. PubMed ID: 27299185
[TBL] [Abstract][Full Text] [Related]
4. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
Wu DW; Wu TC; Chen CY; Lee H
Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
[TBL] [Abstract][Full Text] [Related]
5. Rac1 and Cdc42 differentially modulate cigarette smoke-induced airway cell migration through p120-catenin-dependent and -independent pathways.
Zhang L; Gallup M; Zlock L; Finkbeiner WE; McNamara NA
Am J Pathol; 2013 Jun; 182(6):1986-95. PubMed ID: 23562274
[TBL] [Abstract][Full Text] [Related]
6. Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.
Song P; Song B; Liu J; Wang X; Nan X; Wang J
Clin Transl Oncol; 2021 Apr; 23(4):892-901. PubMed ID: 32974862
[TBL] [Abstract][Full Text] [Related]
7. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
Shuai S; Liao X; Wang H; Liu L; Mei S; Cao J; Wang S
Cancer Sci; 2021 Oct; 112(10):4139-4150. PubMed ID: 34058054
[TBL] [Abstract][Full Text] [Related]
8. PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness.
Chen MJ; Wu DW; Wang YC; Chen CY; Lee H
Sci Rep; 2016 Oct; 6():34933. PubMed ID: 27713506
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
[TBL] [Abstract][Full Text] [Related]
10. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
11. RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation.
Cho JH; You YM; Yeom YI; Lee DC; Kim BK; Won M; Cho BC; Kang M; Park S; Yang SJ; Kim JS; Kim JA; Park KC
Cell Death Dis; 2018 May; 9(6):587. PubMed ID: 29789542
[TBL] [Abstract][Full Text] [Related]
12. Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling.
Wang W; Xia X; Chen K; Chen M; Meng Y; Lv D; Yang H
Front Oncol; 2021; 11():665045. PubMed ID: 34168988
[TBL] [Abstract][Full Text] [Related]
13. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
14. ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration.
Yuan L; Santi M; Rushing EJ; Cornelison R; MacDonald TJ
Clin Exp Metastasis; 2010 Oct; 27(7):481-91. PubMed ID: 20526801
[TBL] [Abstract][Full Text] [Related]
15. Loss of p120ctn causes EGFR-targeted therapy resistance and failure.
Landmesser ME; Raup-Konsavage WM; Lehman HL; Stairs DB
PLoS One; 2020; 15(10):e0241299. PubMed ID: 33112928
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
[TBL] [Abstract][Full Text] [Related]
17. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
Ochi N; Takigawa N; Harada D; Yasugi M; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
Exp Cell Res; 2014 Mar; 322(1):168-77. PubMed ID: 24440771
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
19. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
20. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
